SCHEMBL12089511

SCHEMBL12089511

CC1(C#Cc2cc(C(C)(C)O)ccc2N2CCN(S(=O)(=O)c3cccs3)CC2)COC1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GCK P35557 2/20 0.45
GCKR Q14397 2/20 0.45
PKM P14618 4/20 0.41
MAPT P10636 4/20 0.41
JAK2 O60674 1/20 0.41
GAA P10253 1/20 0.41
TSHR P16473 1/20 0.41
GALR3 O60755 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 2/20 0.39
USP2 O75604 1/20 0.39
MAPK1 P28482 1/20 0.39
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
BACE1 P56817 1/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15940 0.93 GCK (0.49) GCKGCKR
SCHEMBL12078823 0.93 GCK (0.49) GCKGCKR
SCHEMBL18514 0.93 GCK (0.49) GCKGCKR
SCHEMBL18403 0.88 MAPT (0.51) PKMMAPTJAK2GAATSHR
SCHEMBL15941 0.87 GCKR (0.42) GCKGCKRPKMMAPTJAK2
SCHEMBL12090247 0.85 GCKR (0.51) GCKGCKRPKMMAPTJAK2
SCHEMBL12089974 0.83 GCK (0.48) GCKGCKRPKMMAPTJAK2
SCHEMBL12089900 0.82 GCKR (0.48) GCKGCKRPKMMAPTJAK2
SCHEMBL12090099 0.82 GCKR (0.48) GCKGCKRPKMMAPTJAK2
SCHEMBL12089901 0.82 MAPT (0.46) GCKGCKRPKMMAPTJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 GCK 2/4885GCKR 1/4885PKM 197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.